InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,620.85
(
0.42%
)
US TECH 100
19,332.00
(
0.63%
)
Dow Jones
40,890.49
(
0.14%
)
Brent Oil
75.64
(
-0.06%
)
Bitcoin
60,426.19
(
2.40%
)
Post# of 252939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

InTheTrenches

Send PM Follow Ignore
Followers 4
Posts 929
Boards Moderated 0
Alias Born 08/15/2006

InTheTrenches

Re: None

Thursday, 03/21/2019 5:34:20 PM

Thursday, March 21, 2019 5:34:20 PM

Post# of 252939
Neurotrope, which is the last company running trials in moderate-to-severe Alzheimer's patients, may be worth a look, going into late-summer readout:

Neurotrope approaches Alzheimer's as a disease of synaptic loss (starting in the hippocampus). Their drug Bryostatin regrows synapses, clears Amyloid-Beta and Tau, and is neuro-protective.

https://247wallst.com/healthcare-business/2019/03/21/is-neurotrope-the-default-alzheimers-winner-after-biogens-implosion/
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up